Detailed information for compound 1568301

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 359.446 | Formula: C17H21N5O2S
  • H donors: 2 H acceptors: 4 LogP: 2.11 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: NCCc1c(C)nc2n(c1C)nc(c2S(=O)(=O)c1ccccc1)NC
  • InChi: 1S/C17H21N5O2S/c1-11-14(9-10-18)12(2)22-17(20-11)15(16(19-3)21-22)25(23,24)13-7-5-4-6-8-13/h4-8H,9-10,18H2,1-3H3,(H,19,21)
  • InChiKey: TUVYXOIGALSWMM-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Echinococcus multilocularis tm gpcr rhodopsin gpcr rhodopsin superfamily Get druggable targets OG5_145685 All targets in OG5_145685
Echinococcus granulosus tm gpcr rhodopsin Get druggable targets OG5_145685 All targets in OG5_145685
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus granulosus thymidylate synthase 0.0339 0.1757 0.1757
Echinococcus multilocularis tm gpcr rhodopsin gpcr rhodopsin superfamily 0.1003 0.6931 0.6931
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.1396 1 1
Leishmania major dihydrofolate reductase-thymidylate synthase 0.0959 0.6587 1
Schistosoma mansoni dihydrofolate reductase 0.1396 1 1
Mycobacterium tuberculosis Probable thymidylate synthase ThyA (ts) (TSASE) 0.0339 0.1757 0.144
Loa Loa (eye worm) hypothetical protein 0.0228 0.0892 0.0892
Trichomonas vaginalis histone deacetylase, putative 0.0228 0.0892 1
Echinococcus multilocularis histone deacetylase 1 0.0228 0.0892 0.0892
Schistosoma mansoni histone deacetylase 0.0228 0.0892 0.0892
Echinococcus granulosus dihydrofolate reductase 0.1396 1 1
Echinococcus multilocularis histone deacetylase 6 0.012 0.0047 0.0047
Trichomonas vaginalis histone deacetylase, putative 0.0228 0.0892 1
Trypanosoma cruzi histone deacetylase 1, putative 0.0228 0.0892 0.1355
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.1396 1 1
Trichomonas vaginalis histone deacetylase, putative 0.0228 0.0892 1
Schistosoma mansoni histone deacetylase 0.0228 0.0892 0.0892
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 0.0959 0.6587 1
Brugia malayi Histone deacetylase 1 0.0228 0.0892 0.0892
Loa Loa (eye worm) histone deacetylase 1 0.0228 0.0892 0.0892
Plasmodium vivax histone deacetylase 1, putative 0.0228 0.0892 0.1355
Loa Loa (eye worm) thymidylate synthase 0.0339 0.1757 0.1757
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.0959 0.6587 1
Echinococcus multilocularis thymidylate synthase 0.0339 0.1757 0.1757
Toxoplasma gondii histone deacetylase HDAC3 0.0228 0.0892 0.1355
Echinococcus granulosus histone deacetylase 6 0.012 0.0047 0.0047
Echinococcus multilocularis histone deacetylase 3 0.0228 0.0892 0.0892
Brugia malayi histone deacetylase 1 (HD1) 0.0228 0.0892 0.0892
Leishmania major histone deacetylase, putative 0.0228 0.0892 0.1355
Onchocerca volvulus 0.0339 0.1757 0.5
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.1396 1 1
Trichomonas vaginalis histone deacetylase, putative 0.0228 0.0892 1
Trichomonas vaginalis histone deacetylase 1, 2 ,3, putative 0.0228 0.0892 1
Brugia malayi hypothetical protein 0.0161 0.037 0.037
Brugia malayi Dihydrofolate reductase 0.1396 1 1
Echinococcus granulosus histone deacetylase 1 0.0228 0.0892 0.0892
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 0.0959 0.6587 1
Chlamydia trachomatis dihydrofolate reductase 0.1396 1 0.5
Trichomonas vaginalis histone deacetylase 1, 2 ,3, putative 0.0228 0.0892 1
Echinococcus multilocularis dihydrofolate reductase 0.1396 1 1
Brugia malayi thymidylate synthase 0.0339 0.1757 0.1757
Trichomonas vaginalis histone deacetylase, putative 0.0228 0.0892 1
Entamoeba histolytica histone deacetylase, putative 0.0228 0.0892 0.5
Trypanosoma cruzi histone deacetylase 1, putative 0.0228 0.0892 0.1355
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.0959 0.6587 1
Schistosoma mansoni bifunctional dihydrofolate reductase-thymidylate synthase 0.0339 0.1757 0.1757
Leishmania major histone deacetylase, putative 0.0228 0.0892 0.1355
Echinococcus granulosus tm gpcr rhodopsin 0.1003 0.6931 0.6931
Giardia lamblia Histone deacetylase 0.0228 0.0892 0.5
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase, putative 0.0161 0.037 0.0562
Trypanosoma brucei histone deacetylase 1 0.0228 0.0892 0.1355
Toxoplasma gondii histone deacetylase HDAC2 0.0228 0.0892 0.1355
Schistosoma mansoni histone deacetylase hda2 0.012 0.0047 0.0047
Trichomonas vaginalis histone deacetylase 1, 2 ,3, putative 0.0228 0.0892 1
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.0959 0.6587 1
Loa Loa (eye worm) dihydrofolate reductase 0.1396 1 1
Trichomonas vaginalis histone deacetylase, putative 0.0228 0.0892 1
Brugia malayi histone deacetylase 3 (HD3) 0.0228 0.0892 0.0892
Echinococcus granulosus histone deacetylase 3 0.0228 0.0892 0.0892
Plasmodium falciparum histone deacetylase 1 0.0228 0.0892 0.1355
Loa Loa (eye worm) histone deacetylase 3 0.0228 0.0892 0.0892

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.645 nM BindingDB_Patents: Competitive Assay. Screening of the disclosed compounds for their potential ability to interact with serotonin 5-HT6 receptors was carried out by method of radioligand binding. For this purpose membrane species were prepared from expressing recombinant human 5-HT6 receptors HeLa cells by means of their homogenization in glass homogenizer with subsequent separation of plasmatic membranes from cell nucli, mitochondria's and cell wreckages by differential centrifugation. Determination of tested compounds binding to 5-HT6 receptors was carried out according to the method described in [Monsma F J Jr, Shen Y, Ward R P, Hamblin M W and Sibley D R, Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43:320-327, 1993]. ChEMBL. No reference
IC50 (binding) = 0.645 nM BindingDB_Patents: Competitive Assay. Screening of the disclosed compounds for their potential ability to interact with serotonin 5-HT6 receptors was carried out by method of radioligand binding. For this purpose membrane species were prepared from expressing recombinant human 5-HT6 receptors HeLa cells by means of their homogenization in glass homogenizer with subsequent separation of plasmatic membranes from cell nucli, mitochondria's and cell wreckages by differential centrifugation. Determination of tested compounds binding to 5-HT6 receptors was carried out according to the method described in [Monsma F J Jr, Shen Y, Ward R P, Hamblin M W and Sibley D R, Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43:320-327, 1993]. ChEMBL. No reference
IC50 (binding) = 45 nM BindingDB_Patents: Functional Assay. Determination of antagonistic activity of compounds of the general formula 1 towards 5-HT6 receptors. Compounds of the general formula 1 were tested for their ability to prevent 5-HT6 receptors activation by serotonin. HEK 293 cells (cells of human embryo's kidney) with artificially expressed 5-HT6 receptor, activation of which by serotonin leads to increasing the concentration of intracellular cAMP, were used. The level of intracellular cAMP was determined using reagent kit LANCE cAMP (PerkinElmer) according to the method described by the manufacturer of the kit [http://las.perkinelmer.com/content/Manuals/MAN_LANCEcAMP384KitUser.pdf]. Effectiveness of the compounds was estimated by their ability to reduce the level of intracellular cAMP induced by serotonin. Table 4 presents IC50 values for the compounds of general formula 1 in the setting of functional assay for serotonin 5-HT6 receptor inhibition. The data given testify their moderate or high antagonistic activity. ChEMBL. No reference
IC50 (binding) = 45 nM BindingDB_Patents: Functional Assay. Determination of antagonistic activity of compounds of the general formula 1 towards 5-HT6 receptors. Compounds of the general formula 1 were tested for their ability to prevent 5-HT6 receptors activation by serotonin. HEK 293 cells (cells of human embryo's kidney) with artificially expressed 5-HT6 receptor, activation of which by serotonin leads to increasing the concentration of intracellular cAMP, were used. The level of intracellular cAMP was determined using reagent kit LANCE cAMP (PerkinElmer) according to the method described by the manufacturer of the kit [http://las.perkinelmer.com/content/Manuals/MAN_LANCEcAMP384KitUser.pdf]. Effectiveness of the compounds was estimated by their ability to reduce the level of intracellular cAMP induced by serotonin. Table 4 presents IC50 values for the compounds of general formula 1 in the setting of functional assay for serotonin 5-HT6 receptor inhibition. The data given testify their moderate or high antagonistic activity. ChEMBL. No reference
Ki (functional) = 8.86 Inhibition of human recombinant 5-HT6 receptor expressed in human HEK293 cells assessed as inhibition of serotonin-induced cAMP accumulation ChEMBL. 22029285

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.